Success Metrics

Active Trials

2(40%)

Phase Distribution

Ph phase_1

40%

Ph phase_2

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Terminated(1)

Detailed Status

Not yet recruiting2

Recruiting1

Active, not recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 12 (40.0%)

Phase 23 (60.0%)

Trials by Status

not_yet_recruiting240%

recruiting120%

active_not_recruiting120%

withdrawn120%

Recent Activity

2 active trials

Showing 5 of 5

recruitingphase_1

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT06622005

withdrawnphase_1

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT07082270

active_not_recruitingphase_2

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT06169215

not_yet_recruitingphase_2

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

NCT06948084

not_yet_recruitingphase_2

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

NCT07485647

Clinical Trials (5)

Showing 5 of 5 trials

NCT06622005Phase 1

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting

NCT07082270Phase 1

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Withdrawn

NCT06169215Phase 2

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Active Not Recruiting

NCT06948084Phase 2

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Not Yet Recruiting

NCT07485647Phase 2

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5